Anteris Technologies Global Corp. (AVR)
$6.45-3.01%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $237M
- Beta
- 0.73
- P/E (TTM)
- -2.34
- Short % float
- 26.53%
- Days to cover
- 7.7
- SI change
- +3.9%
- 1W
- -8.51%
- 1M
- -26.03%
- vs SPY 1W
- -8.37%
- vs SPY 1M
- -28.54%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 4
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-46.6%
REV YoY-
ROE-77.7%
EPS YoY-
ROA-38.0%
GROSS37
OP-4738
NET-4620
[VALUATION]
P/E TTM-2.34
P/E FWD-
SECTOR PE20.34
INDUSTRY PE22.66
P/B2.50
P/FCF-
EV/EBITDA-3.71
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.32
ALTMAN Z-
CURR RATIO14.20
ND/EBITDA-
BETA0.73
Company news
FAQ
- What is LOPJLB’s current signal on AVR?
- LOPJLB’s latest quantitative signal on Anteris Technologies Global Corp. (AVR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AVR in?
- Anteris Technologies Global Corp. (AVR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Anteris Technologies Global Corp. (AVR) do?
- Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the …